Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Shifts Its Focus From Products To Pipeline, But Stays In Comfort Zone

Executive Summary

Amgen Inc. is sticking to what it knows as it finally moves some of its mid-stage pipeline into later stages. Two of its most promising pipeline candidates, AMG 827 and AMG 785, are intended to be follow-on products to two of Amgen’s biggest franchises: Enbrel (etanercept) and Prolia/Xgeva (denosumab).

Related Content

Amgen Rethinks Ganitumab After Longshot Pancreatic Cancer Trial Fails
A Maturing Amgen Focuses On Capital Allocation, Late-Stage Pipeline
Radius Raises $91 Million, Moves Toward Public Listing
Radius Takes $91MM To Support Osteoporosis Drug, Moves Toward Public Listing
Amgen's Bone Drug Xgeva Delays Pain From Prostate Cancer Metastases
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal
Amgen Obtains Broader Label For Denosumab With Oncology Indication
Market Snapshot: Anti-TNFs Grow Despite Tough Market
Market Snapshot: Anti-TNFs Grow Despite Tough Market





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts